Merck, Simcere team up in China

Merck has inked a joint venture partnership with China's Simcere Pharmaceutical Group. In addition to vaccines, which the two companies already market together, Simcere and Merck will market and manufacture cardiovascular and metabolic drugs. The joint venture also covers some development work, though Merck's release didn't provide any details about that aspect of the deal. Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.